The C12orf43 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the HT29 colorectal adenocarcinoma cell line, designed to disrupt the C12orf43 gene. This knockout model enables investigation of the gene’s functional role in colorectal cancer. The polyclonal format offers a heterogeneous genetic background, allowing studies of gene disruption effects without clonal bias.
The parental HT29 cell line is a well-characterized model of human colorectal adenocarcinoma, isolated from a 44-year-old female. These adherent epithelial cells carry mutations in p53, APC, and KRAS, and exhibit microsatellite stability with chromosomal instability, reflecting common colorectal cancer genomic features. HT29 cells are widely used to study intestinal epithelial biology, tumor progression, and drug resistance, making them an appropriate host for assessing C12orf43 loss.
C12orf43 is a poorly characterized gene that drives colorectal cancer cell proliferation and invasion through activation of the PI3K/AKT pathway. Mechanistically, it acts downstream of Wnt/??-catenin and MYC and promotes signaling via AKT phosphorylation, leading to upregulation of cyclin D1, CDK4, and matrix metalloproteinases MMP2 and MMP9. While direct interacting partners remain unknown, C12orf43 may interact with PI3K regulatory subunits to facilitate signal transduction. Loss of C12orf43 attenuates PI3K/AKT/mTOR signaling, reducing cyclin D1 and MMP expression, thereby impairing cell cycle progression and invasive capacity.
In the HT29 context, C12orf43 knockout provides a physiologically relevant platform to explore oncogenic signaling dependencies. With mutant APC driving Wnt/??-catenin activity, this model allows dissection of potential crosstalk with C12orf43-mediated PI3K/AKT effects. HT29 cells are also frequently used in drug resistance research; C12orf43 disruption may illuminate roles in chemosensitivity. The polyclonal population captures diverse CRISPR edits, ensuring robust functional readouts across genetic backgrounds.
These cells are suited for a range of functional genomics applications, including proliferation (MTT, BrdU), colony formation, Transwell invasion/migration, and cell cycle analysis by flow cytometry. Western blotting for phospho-AKT and RT-qPCR for downstream targets (CCND1, MMP2, MMP9) can confirm pathway modulation. Apoptosis assays further explore survival mechanisms. This model supports validation of oncogenic targets, PI3K/AKT pathway studies, and investigation of colorectal cancer drug resistance. For further details, please contact Ascent Research.
